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To assess the role of crystalhnity in btological response, we quantttated the generation of reactive oxygen metabolites in human polymorphonuclear 
leukocytes (PMN) with a chemiluminescence assay using three hydroxyapatite preparations with sintering temperatures of 1,200”C and 900°C and 
a drying temperature of 110°C on the basis of equal weights (1 mg/ml). These crystals have almost the same average diameters and similar average 
zeta potentials. The crystals prepared at higher temperatures have htgher crystalhnity. or larger domain sizes, which were calculated by X-ray 
diffraction line broadening. The production of reactive oxygen metabohtes by PMN in hydroxyapattte of 1,200”C was lo-times that by PMN in 
hydroxyapatite of 900°C and more than 50-times greater than that in hydroxyapattte of 110°C. A single linear correlation was observed for a plot 
of log (peak chemthrminescence levels) vs. a plot of log (domain sizes). These results clearly show that the maximal effect of crystalhnity on 
hydroxyapatite-induced production of reactive oxygen metabolites by human PMN was seen at higher crystallinity. 
Crystal: Chemiluminescence; Domain size; Sintering temperature 
1. INTRODUCTION 
Hydroxyapatite crystals are the inorganic constituent 
of osseous and dental tissues, and synthetic hydrox- 
yapatites are interesting biomaterials. On the other 
hand, the deposition of hydroxyapatite microcrystals in 
tissues is associated with pathological syndromes. Hy- 
droxyapatite is associated with gout-like attacks in sev- 
eral patients [l], is present in approximately 40% of all 
kidney stones [2], and is found in numerous other soft 
tissue calcifications [3]. The interaction between hy- 
droxyapatite microcrystals and cells is involved in nu- 
merous aspects of both normal and pathological apatite 
depositions. Therefore, the study of hydroxyapatite-cell 
interaction is of considerable interest. 
Synthetic hydroxyapatite has been prepared by a va- 
riety of sintering temperatures [4]. Jarcho [5] described 
hydroxyapatite fired at higher temperatures as showing 
increasing grain growth and opacity, although the com- 
position determined by X-ray diffraction was still 100% 
hydroxyapatite. The various sintering temperatures of 
hydroxyapatite provide a unique opportunity to study 
cell interactions with crystals having different crystallin- 
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ity while maintaining a nearly constant lattice. Mi- 
crocrystals placed in the body will stimulate phagocytic 
cells and induce host reactions [6.7]. Polymorphonu- 
clear leukocytes (PMN) are important phagocytic cells 
in the initial non-specific reaction. Reactive oxygen me- 
tabolites formed by phagocytic cells have biological ef- 
fects on the development of host reactions, e.g. damage 
to DNA [8], inactivation of alpha-1-antiprotease en- 
zyme-binding capacity [9], and bioactivation of chemi- 
cal carcinogens [lo]. Therefore, it is very important to 
study the interaction between different crystallinities of 
hydroxyapatite and PMN. In this study we determined 
the effect of crystallinity on the generation of reactive 
oxygen metabolites in human PMN with a chemilumi- 
nescence assay using three hydroxyapatite preparations 
with different sintering temperatures in order to better 
define the role of crystallinity in crystal-cell interac- 
tions. 
2. MATERIALS AND METHODS 
2.1. Matrrlals 
For this study, three types of hydroxyapattte were prepared by 
Mitsubishi Materials Co.. Tokyo, Japan. They were prepared using 
a slow precipitatton method mvolving aqueous Ca(OHb and H,PO, 
at 40°C and careful digestion and extraction procedures. Then they 
were sintered at 1,200”C and 900°C. or dried at 110°C without sinter- 
ing. respecttvely. The crystals were ground down to the desired particle 
size. The protein content of these particles was checked by the direct 
Nmhydrin reaction and Bradford’s method using Coomassie brilhant 
blue [I 11. No trace of protein appeared. The crystals were verified to 
be pyrogen-free by the hmulus amebocyte lysate assay (Sigma Co., St. 
Louis, MO) following FDA guidelines [12]. These particles were 
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Fig. 1. X-ray diffraction patterns of the three hydroxyapatite particles 
measured by Model RU-200. 
round. We have designated the three types of hydroxyapatite as 
1,2OO”C, 900°C. and 110°C. 
2.2. X-ruI> analysis and line broadenrng 
Confirmation of crystal structure and purity was obtamed by high 
resolution X-ray powder diffraction with monochromatic CuKa radi- 
ation on a rotating anode X-ray generator (Rigaku. Model RU-200 
and RINT-2400, Tokyo. Japan). Measurements by Model RU-200 
were made using the step-scanning technique (40 kV. 100 mA; 4”/min) 
in the range of 28=5560” at room temperature. Patterns were com- 
pared to a known hydroxyapatite standard. Measurements by Model 
RINT-2400 were made usmg the step-scanning technique (40 kV. IO0 
mA; 0.5”/mm) m the range of 219=25527” for the (002) and m the 
range of 28=30-35” for the (300) at room temperature. Following 
standard methods [13]. the peak width at half height was measured for 
(002) and (300) diffraction maxima from densitometer tracings Do- 
main sizes were calculated using the Scherrer equation [13]. The mstru- 
mental line broadening was determined to be 0.105” 26 using a sample 
of quartz. The size of the quartz crystals was determined to be 
36.2 + 13 pm by direct measurement of particles in a scanning micro- 
graph (Model JSM-T20: JEOL Ltd., Tokyo. Japan). The X-ray dif- 
fraction patterns of this series of synthetic hydroxyapatites showed 
sharpening of the apatite peaks with increased sample heating temper- 
atures (Fig. 1). 
2.3. Infrared spectroscop? 
Infrared spectra were made of all specimens on an Infrared spec- 
trum’s analyzer (Shimadzu. Model FTIR-4000, Kyoto, Japan) operat- 
ing in the absorbance mode. KBr pellets were used m order to facilitate 
quantitation of the results. All specimens exhibited apparently sym- 
metric 630-640 cm-’ OH- stretch peaks. In the samples prepared at 
high temperatures, the OH- stretch band exhibited pronounced asym- 
metry (toe extending toward lower frequencies), similar to that dis- 
cussed by Cant et al. [14] in spectra taken at elevated temperatures [4]. 
2.4. Particle measurements 
Crystal sizes were determined using a particle size analyzer (Model 
SALD-1100; Shimadzu, Kyoto, Japan). The surface areas were meas- 
ured with a surface area analyzer ( Model Monosorb. MS-13; Yuasa- 
Ionics Corp., Osaka, Japan). One-point Brunauer-Emmett-Teller 
(BET) surface area determinations were made using nitrogen (adsor- 
bate) in helium (carrier) gas mixtures. Fig. 2 shows the crystal size 
distribution, average crystal diameter, and specific surface area for 
each of the three types of hydroxyapatite used m this study These 
crystals have almost the same average diameters of 3.0.3.2 and 3.4pm. 
respectively. About 3 pm was chosen because our previous study 
showed that the 3.2;um alumina fraction demonstrated the highest 
induction of reactive oxygen metabolites in PMN and mononuclear 
leukocytes when we quantitated the generation with a chemilumines- 
cence assay using 6 alpha-alumma preparations with average diame- 
ters of 0.6. 0.8. 3.2, 7.5. 28 and 68 pm on an equal weight (1 mg/ml) 
and surface area (100 cm*/ml) basis [I 51. Our preliminary study 
showed that in each of the three hydroxyapatite preparations about 
3 pm of the hydroxyapatite fraction demonstrated the highest induc- 
tion of reactive oxygen metabolites in PMN when we quantitated the 
generation with a chemilummescence assay using 16 hydroxyapatite 
preparations with average diameters of 1 .O. 1.6. 3.0. 5.4, 7.2 and 9.5 
pm in 1,2OO”C, 1.0, 1.6. 3.2. 5.4, 7.2 and 9.2pm in 9OO”C, and 3.4. 
5.1. 7.1 and 8.7pm in 110°C on an equal weight (1 mg/ml) basis. The 
zeta potential (a measure of the crystal surface charge) was determined 
usmg a zeta potential analyzer (System-3000: Penkem) for each of the 
hydroxyapatite samples suspended in distilled water. These crystals 
have similar average zeta potentials of -12.2, -8.1 and -13.2 mV in 
1,2OO”C, 900°C and 1 lO”C, respectively. 
2.5. PMN rsolutlon 
PMN were isolated by Ficoll-Hypaque density centrifugation from 
heparinized human venous blood, obtained from apparently healthy 
adults. PMN were removed separately, washed in Dulbecco’s phos- 
phate buffered saline (PBS), and counted More than 98% of the cells 
were PMN, as assessed from WrighttGimsa stained smears, and the 
level of cell viability exceeded 99% as determined by Trypan blue dye 
exclusion 
2.6. Chemdumine~cence assq 
Chemiluminescence was measured with an automatic microcom- 
puter-controlled luminescence analyzer (LB 9505 AT; Berthold, Ger- 
many) at 37°C. The reaction mixture (final total volume 1.0 ml) 
consisted of 2040 ~1 of leukocyte suspension (final concentration 
5 x IO5 cells/ml); 20 ~1 of 10m4 M luminol (5-amino, 3,3-dihydro, 1,4- 
phthalazine-dione) (Tokyo Kasei Kogyo, Tokyo, Japan) m Dul- 
becco’s modified Eagle’s medium (MEM): and 100 ~1 of hydrox- 
yapatite particles suspended m PBS (final concentration 1 mg/ml). The 
chemiluminescence output was monitored for 20 min after particles 
were added to the cells. Results were expressed as counts per minute 
(cpm) per 5 x 10’ cells. Cell-free reaction mixtures with hydroxyapatite 
caused no CL responses. 
2.7. Statisticul analws 
Data points indicated the means t S.D. One factor analysis of vari- 
ance (ANOVA) with repeated measures was used to evaluate the effect 
of crystallinity on hydroxyapatite-induced production of reactive oxy- 
gen metabolites by PMN. Differences between treatment means were 
determined by the Scheffe procedure. The 0.05 level was used as the 
criterion of statistical significance. Coefficients of correlation were 
calculated by standard statistical methods. 
20 -I 
Fig. 2. Crystal size distribution of the three hydroxyapatite particles 
used in this study. The average crystal diameter and specific surface 
area are included for each particle. 
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Fig. 3. Kinetics of chemiluminescence of polymorphonuclear leuko- 
cytes (PMN) induced by hydroxyapatite particles with sintering tem- 
perature of 1,200”C and 900°C and with drying temperature of 110°C. 
and Dulbecco’s phosphate buffer salme (PBS). 
3. RESULTS 
Fig. 3 shows the kinetics of chemiluminescence of 
PMN induced by hydroxyapatite particles with sinter- 
ing temperatures of 1,200”C and 900°C or a drying 
temperature of 110°C on an equal weight basis. Hy- 
droxyapatite particles induced PMN chemilumines- 
cence in the following order of magnitude: 
1,200”C > 900°C > 110°C > PBS. Peak chemilumines- 
cence levels were reached at 6.1, 5.6, 6.9 and 7.2 min in 
1,200”C. 900°C 110°C and PBS, respectively. The pro- 
duction of reactive oxygen metabolites by PMN in hy- 
droxyapatite of 1,200”C was lo-times that by PMN in 
hydroxyapatite of 900°C and more than 50-times 
greater than that in hydroxyapatite of 110°C. One fac- 
tor ANOVA with repeated measures showed that signif- 
icant differences were present among 1 ,200°C, 900” C, 
110°C and PBS, except between 110°C and PBS. 
Fig. 4 shows the correlation between peak chemilumi- 
nescence level and the domain size calculated from the 
line broadening of the (300) and (002) diffraction max- 
ima for each crystal. After removing the component of 
the line broadening which was due to the instrument, no 
attempt was made to separate the experimentally deter- 
mined line broadening into the components due to do- 
main size and atomic substitutions. This may explain 
some of the scatter in the domain size vs. chemilumines- 
cence response. Although line broadening analysis is 
more accurate when used to determine domain sizes less 
than 1,000 A [4], a single linear correlation is observed 
for a plot of log (peak chemiluminescence levels) vs. a 
plot of log (domain sizes) for both the (300) and (002). 
The coefficient for the (300) was Y = 0.997, P < 0.05, 
while that for the (002) was r = 1.000. P < 0.01. 
4. DISCUSSION 
It has been demonstrated that host defense reactions 
to particles by phagocytic cells are largely affected by 
size and the surface properties of the particles, especially 
the chemical structure of the surface and surface charge 
[16-191. In the present study we found that the crystals 
prepared at lower temperatures, which have more sur- 
face area and almost the same average diameter and 
similar average zeta potentials, induced less chemilumi- 
nescence than the others. The difference in chemilumi- 
nescence was apparently due to a difference in sintering 
temperature, or a difference in the crystallinity of the 
hydroxyapatite. A study of the hemolytic potential in- 
duced by hydroxyapatite suggests that the crystal-cell 
interactions may be a crystallinity-related phenomenon 
[4]. which was also seen in the case of monosodium 
urate monohydrate [20]. Wiessner et al. [21] compared 
four different silicon dioxide and two different titanium 
dioxide crystals. Similar to our results, they demon- 
strated that biological activity seemed to correlate with 
percent occupied volumes which were calculated using 
known crystallographic data for each of the crystals. 
Hydroxyapatite is an anisotropic structure with hexago- 
nal symmetry [22]. The six-fold rotation axis is the crys- 
tallographic z-axis and is related to the (002) diffraction 
maxima. The diffraction maxyima (300) is related to 
other structural features of hydroxyapatite lattice that 
do not experience the degree of long-range order ob- 
served along the (002) [4]. It is for these reasons that the 
correlations between domain size and chemilumines- 
cence for these sets of maxima are different. Although 
some studies showed no difference in bonding between 
hydroxyapatite and bone tissue at different sintering 
temperatures [23], the greater phlogistic potential of 
higher crystallinity of crystals or ceramics in clinical use 
needs to be taken into consideration. Our findings pro- 
vide further evidence that the qualitative nature of crys- 
tallinity may play a controlling role in phagocytic cell 
function. 
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